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Abstract
Background: Functional Bowel Disorders (FBD) are chronic disorders that are difficult to treat
and manage. Many patients and doctors are dissatisfied with the level of improvement in symptoms
that can be achieved with standard medical care which may lead them to seek alternatives for care.
There are currently no data on the types of Complementary and Alternative Medicine (CAM) used
for FBDs other than Irritable Bowel Syndrome (IBS), or on the economic costs of CAM treatments.
The aim of this study is to determine prevalence, types and costs of CAM in IBS, functional diarrhea,
functional constipation, and functional abdominal pain.
Methods: 1012 Patients with FBD were recruited through a health care maintenance organization
and followed for 6 months. Questionnaires were used to ascertain: Utilization and expenditures
on CAM, symptom severity (IBS-SS), quality of life (IBS-QoL), psychological distress (BSI) and
perceived treatment effectiveness. Costs for conventional medical care were extracted from
administrative claims.
Results: CAM was used by 35% of patients, at a median yearly cost of $200. The most common
CAM types were ginger, massage therapy and yoga. CAM use was associated with female gender,
higher education, and anxiety. Satisfaction with physician care and perceived effectiveness of
prescription medication were not associated with CAM use. Physician referral to a CAM provider
was uncommon but the majority of patients receiving this recommendation followed their
physician's advice.
Conclusion: CAM is used by one-third of FBD patients. CAM use does not seem to be driven by
dissatisfaction with conventional care. Physicians should discuss CAM use and effectiveness with
their patients and refer patients if appropriate.
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Complementary and Alternative Medicine (CAM) thera-
pies are growing in popularity. Between 1997 and 2002
about 35% of the US population -equaling 72 million
adults- reported using CAM [1]. The use of CAM is most
popular among patients who have difficult-to-treat
chronic medical conditions for which conventional med-
icine does not provide effective treatments [2]. These
patients often use CAM to augment, and sometimes even
replace, conventional treatments. Functional bowel disor-
ders (FBD) are an example of such chronic, difficult-to-
treat conditions. FBD refers to a disorder of the bowels
where the primary abnormality is an altered physiological
function rather than a problem that has an identifiable
structural or biochemical cause. FBDs cannot be diag-
nosed trough traditional means, such as physical exami-
nation, x-ray, laboratory tests or endoscopy. The most
common FBD is Irritable Bowel Syndrome (IBS) which is
characterized by abdominal pain and changes in stool
consistency and/or stool frequency [3]. FBDs are common
chronic disorders with approximately 30 million people
in North America meeting the diagnostic criteria for IBS
alone. FBDs are associated with high health care costs and
health care seeking [4,5].
Since no identifiable disease processes are known to cause
FBDs, treatment is focused on managing symptoms rather
than affecting a cure. Many patients and doctors are dissat-
isfied with the level of symptom improvement that can be
achieved with standard medical care [6] possibly leading
many patients to seek alternative care for their symptoms.
Some data are available on CAM use in Irritable Bowel
Syndrome. A population-based study showed that 20.8%
of IBS patients sought care from an alternative health care
provider [7] and among IBS outpatients in a gastroenter-
ology clinic in the UK, the prevalence of self-prescribed
complementary and alternative oral medicines was 50.9%
[8]. However, for other FBDs, such as functional constipa-
tion, there is no published data on CAM use. Although the
literature is still sparse, there has been a rise in the number
of studies on the effectiveness of CAM; for reviews of this
literature see Tillisch [9] and Hussain & Quigley [10].
Three recent Cochrane reviews evaluate the somewhat
more extensive literature on hypnosis [11], herbal medi-
cines [12] and acupuncture [13] for the treatment of IBS,
however their analyses were based on only 4 studies for
hypnosis and 6 for acupuncture. Although 75 studies were
included in the Cochrane review for herbal medicine,
93% of these were conducted and published in Chinese
and thus unavailable to most readers outside of China.
Despite the increased acceptance and awareness of CAM,
there are currently no data on the types of CAM that are
used for FBDs other than IBS, or the economic cost of
CAM treatments. This study aims to present data on the
prevalence and different types of CAM used in IBS, func-
tional diarrhea, functional constipation, and functional
abdominal pain, as well as associated costs and perceived
effectiveness. A second aim of the study is to identify
patient characteristics that discriminate patients who use
CAM therapies from those who do not. A third aim is to
determine how often CAM therapies are recommended by
physicians, and how these recommendations are per-
ceived and acted upon by patients with FBD.
Methods
Setting
Data were derived from the Managing Abdominal Pain
Study [14], which was carried out in 2001–2002 at Group
Health Cooperative of Puget Sound, a 525,000 member
health maintenance organization (HMO) in Seattle. The
study surveyed patients in the care of 353 primary care
physicians and 16 gastroenterology specialists in the
HMO.
Design
This study was a part of a larger investigation of standard
medical care for FBDs which has been described elsewhere
[5]. To identify patients with FBD, all patient encounter
forms submitted by primary care and gastroenterology
clinic physicians were prospectively screened for IBS
(ICD-9CM code 564.1), abdominal pain (789.X), consti-
pation (564.0), or diarrhea (787.91). This process identi-
fied patients soon after they had consulted for diagnosis
and treatment of a GI complaint: This was their index
visit. Patients who met inclusion criteria were mailed an
invitation to participate in the study, an informed consent
statement, consent to review their medical records (to
exclude anyone with subsequent diagnosis of organic dis-
ease) and the first set of questionnaires, usually within
two weeks of their index visit. A second set of question-
naires was sent 6 months later. Subjects were offered a $10
incentive for completing each of the surveys. This study
was reviewed and approved by the institutional review
boards of Group Health Cooperative, the University of
Washington, and the University of North Carolina at
Chapel Hill.
CAM use and costs
Six months after the index visit, participants were asked
about CAM use and cost in the previous 3 months. Recall
was limited to 3 months because memory is unreliable
beyond 3 months [15]. Cost was defined as out-of-pocket
expenditures within the last three months, in $10 incre-
ments from $10 to $100 (the highest possible response
was $100 and over). CAM therapies listed were ginger root
or tea, fennel seed, senna tea, psychotherapy, homeo-
pathic, hypnotherapy, massage therapy, biofeedback, acu-
puncture, yoga, aromatherapy, and evening primrose oil.
Patients were also asked to write in any other alternativePage 2 of 7
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listed in the questionnaire. Physician recommendation to
see a CAM provider was assessed at the index visit by
patient report, and percentage adherence to those recom-
mendations (ranging from 0%–100% in 10% incre-
ments) was assessed at the six month follow-up.
In the same questionnaire, subjects were asked about non-
prescription medication and supplement use including
acid reducers, laxatives, anti-diarrheal medications, stool
softeners, gas relief medication, pain medication, anti-
spasmodics, fiber, bran, castor oil packs, enemas, suppos-
itories, and electric heating pads or water bottles.
Treatment effectiveness
Treatment effectiveness for prescription medications,
non-prescription medications and herbal remedies was
measured by self-ratings on a 5 point scale (not at all, a lit-
tle, somewhat, very, and extremely). Percentage satisfac-
tion with physician care at the index visit was recorded.
Symptom improvement at 6 month follow-up was meas-
ured in two ways: (1) change in symptoms since index
visit rated on a 7 point scale (markedly worse, somewhat
worse, a little bit worse, no change, a little better, some-
what better, markedly better) and; (2) patients report of
satisfactory relief of bowel symptoms in past 7 days (yes/
no) [16].
IBS severity and type
The Irritable Bowel Syndrome Severity Scale (IBS-SS) was
used at the index visit. The IBS-SS [17] is a well-validated
questionnaire for determining the overall severity of IBS
symptoms. Predominant bowel activity type was deter-
mined by a single survey question: "In the last 6 months,
would you describe your usual bowel movements as...?"
The response options were "normal", "mostly diarrhea",
"mostly constipation" or "changes back and forth".
Psychological Distress and Quality of Life
Quality of life was assessed with the Irritable Bowel Syn-
drome Quality of Life Scale (IBS-QoL) [18]. This is a 34-
item disease-specific quality of life measure for IBS, which
has high internal consistency and reproducibility and has
been shown to be responsive to changes in IBS symptom
severity.
Psychological symptoms were assessed with the Brief
Symptom Inventory-18 (BSI) [19]. This questionnaire
quantifies the symptoms of depression, anxiety and soma-
tization over the previous 7 days, and also provides a glo-
bal severity index reflecting overall psychological distress.
Due to the survey nature of this study, a slightly modified
version of the BSI was used that omitted one question
inquiring about suicidal thoughts, and the scores were
pro-rated accordingly.
Administrative claims
Administrative claims at the HMO were reviewed for var-
ious categories of direct costs of care for 12 months prior
to the index visit and 12 months after the index visit.
Additional information on the cost components can be
found in a separate report on this study [5]. For each cost
category, lower gastrointestinal (GI) costs were recorded
separately from overall GI and non-GI costs. Health care
costs were categorized as lower GI based on a list of diag-
noses, drug classes, and diagnostic procedures designated
by co-author Andrew Feld, MD, Chief of Gastroenterology
Services for Group Health Cooperative, prior to extracting
the administrative claims data. This list is available upon
request.
Data analyses
Almost all cost data deviated significantly from a normal
distribution, with strong positive skew and kurtosis.
Moreover, cost estimates for CAM therapies and other
out-of-pocket expenditures were truncated, since the max-
imum reportable cost for a 3-month period was "$100 or
more". In the latter case, we used $100 for this category.
Medians and ranges are reported for all patients with FBD
and for the subset of patients who reported using CAM
therapies. Chi-square tests were used to test for differences
across FBD groups in prevalence of CAM use.
Differences between CAM and non-CAM users in demo-
graphics, IBS symptoms, psychological distress and qual-
ity of life were determined by t-tests because these
variables are normally distributed. Logistical regression
analysis was run with CAM use as the dependent variable
and all variables that showed significant univariate associ-
ations with CAM use as independent variables. Non-para-
metric Spearman correlations were used to determine the
association of CAM costs with other health care expendi-
tures and other patient characteristics, to address the non-
normal distribution of the cost data. Alpha was .01 for all
comparisons.
Results
A total of 3024 survey packets were mailed to the selected
patients. 1770 patients completed the initial question-
naires (59%) and 1012 of those completers (66%) also
completed the six-month follow-up questionnaires. The
analyzable sample included 419 patients diagnosed by a
physician as having IBS, 183 with functional diarrhea,
159 with functional constipation, and 251 with func-
tional abdominal pain. Table 1 shows the demographics
of the complete sample.
Complementary and Alternative Medicine Use and Cost
Of the entire sample 35.0% reported using at least one of
the CAM categories. Chi-square tests did not yield signifi-
cant differences across FBD groups in CAM use (see TablePage 3 of 7
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groups were ginger tea/root (13.8%), Massage Therapy
(12.0%) and Yoga (10.2%). 63 Subjects reported other
CAM use other than those listed of which the most com-
mon were: high fiber diet or fiber supplements (N = 7),
yogurt or probiotics (N = 4), ice packs (N = 4), chiroprac-
tic treatment (N = 4) and colon cleanse (N = 3).
Among CAM users, the median cost of all CAMs com-
bined was $200 per year, with a range from $40 to $2200.
For this group the median annual cost of CAM was equal
to that for their non-prescription drugs (median = $200),
about two-thirds of lower GI costs (median = $308),
about one-third of median pharmacy costs (median =
$533), and just over 5% of total HMO health care
expenses (median = $3536). Total health care expendi-
tures and prescription drug costs were similar in CAM
users compared to non-users (Table 4).
Patient characteristics associated with CAM
Table 4 lists patients characteristics associated with CAM
use. CAM users tended to be younger and female, have
higher education, report more IBS symptom severity, less
satisfactory relief of bowel symptoms, more distention,
higher depression, anxiety and somatization scores, lower
quality of life, and spend more on non-prescription drugs.
Logistical regression analysis was run with CAM use as the
dependent variable and all variables that showed signifi-
cant univariate associations with CAM use as independent
variables. Gender (β = -.65; p = .003), college education (β
= .75, p = .000), and anxiety (β = .09, p = .008) signifi-
cantly predicted CAM status (R2 = .11).
Perceived effectiveness of CAM compared to medications 
for FBD
Prescription medications were rated as somewhat, very or
extremely effective by 68.9% (N = 358/519) of patients,
compared to 61.0% (N = 356/583) for non-prescription
medications and 56.4% (N = 118/209) for herbal reme-
dies. CAM users did not rate their prescription medica-
tions as less effective (Mean = 2.9; SD = 1.1) than non-
CAM users (Mean = 3.0, SD = 1.1). The median score was
3 in both groups corresponding with an answer of "some-
what effective".
Referral to CAM providers
At the index visit, 6.4% (N = 65) of the patients were
referred by their physician to a dietician, 6.6% (N = 67) to
a psychologist/psychiatrist and 3.7% (N = 37) to a naturo-
path (naturopaths are physicians on the staff of Group
Health Cooperative who have additional training in CAM
therapies). Average patient confidence ratings in these rec-
ommendations were 51.3% for dieticians, 30.0% for
Table 1: Demographics of the Sample (N = 1012)
Age M = 53.5
SD = 14.0
% Male 24.5%
% Hispanic 3.3%
Race
Caucasian 89.3%
African American 2.9%
Asian 3.6%
Other 4.2%
Married/cohabiting 72.8%
College graduate 44.6%
Table 2: Complementary and Alternative Medicine use and annual cost for IBS and FAP
IBS (N = 419) Functional Abdominal Pain (N = 251)
Use Annual cost in $1 Use Annual cost in $1 
% Median(range) % Median(range)
Herbal Supplements/Tea
Ginger root/tea 14.8 40 (40–320) 10.4 40 (40–240)
Evening Primrose oil 3.8 80 (40–400) 0.8 100 (80–120)
Fennel Seed Tea 4.4 40 (40–200) 1.2 40 (40-40)
Senna Tea 2.4 40 (40–360) 0.8 60 (40–80)
Massage Therapy 12.6 400 (40–400) 14.3 400 (140–400)
Yoga 10.0 80 (40–400) 5.2 80 (40–400)
Psychotherapy 8.1 280 (40–400) 2.4 100 (40–120)
Aromatherapy 7.2 40 (40–220) 5.6 120 (40–400)
Homeopathic Medications 8.1 120 (40–400) 4.4 160 (80–400)
Acupuncture 3.3 180 (40–400) 4.4 400 (40–400)
Biofeedback 1.4 40 (40–240) 0.4 120 (120–120)
Hypnosis 1.4 80 (40–400) 0.0 0 (0-0)
Any CAM 38.4 240 (40–2200) 31.9 240 (40–1280)
1 Data reported for users onlyPage 4 of 7
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month follow up patients were asked how well the physi-
cian's instructions were followed (in increments of 10
from 0%–100%). Patients reported they had followed
their physician's recommendation to see a CAM provider
at least partly in 84.6% of cases for dieticians, 76.1% for
psychologists or psychiatrists, and 83.8% for naturopaths.
Discussion
CAM Prevalence and Cost
About one third of patients who suffer from a FBD use
some type of CAM for their bowel symptoms. Their
median out of pocket cost for CAM is $200 per year,
equaling more than one-third of pharmacy costs and two
thirds of lower GI costs. Prevalence of CAM use in this
study was comparable to CAM use in the general US pop-
Table 3: Complementary and Alternative Medicine use and annual cost for functional diarrhea and constipation.
Functional Diarrhea (N = 183) Functional Constipation (N = 159)
Use Annual cost in $1 Use Annual cost in $1 
% Median(range) % Median(range)
Herbal Supplements/Tea
Ginger root/tea 14.2 40 (40–200) 16.4 40 (40–320)
Evening Primrose oil 3.8 80 (40–280) 1.3 140 (120–160)
Fennel Seed Tea 2.2 40 (40-40) 0.6 40 (40-40)
Senna Tea 1.1 40 (40-40) 8.2 40 (40–240)
Massage Therapy 8.2 280 (120–400) 10.7 360 (80–400)
Yoga 8.7 80 (40–400) 6.9 40 (40–400)
Psychotherapy 2.7 120 (40–400) 2.5 380 (240–400)
Aromatherapy 3.3 40 (40–80) 5.7 120 (40–200)
Homeopathic Medications 6.0 160 (40–400) 4.4 160 (40–400)
Acupuncture 2.7 320 (160–400) 4.4 400 (200–400)
Biofeedback 0.0 0 (0-0) 0.6 40 (40-40)
Hypnosis 0.5 40 (40-40) 0.0 0 (0-0)
Any CAM 33.9 160 (40–920) 32.1 160 (40–1240)
1 Data reported for users only
Table 4: Factors associated with CAM use
CAM (N = 354) No CAM (N = 658) 
Mean(SD) or % Mean(SD) or %
Age 51.4 (13.1) 54.6 (14.3) p < .001
Female 82.5% 71.7% p < .001
College graduate 52.8% 40.2% p < .001
Married/cohabiting 74.7% 69.3% NS
IBS Severity (IBS-SS) 237.6 (121.4) 206.8 (113.6) p < .001
Suffering from Distention 51.7% 40.1% p < .001
Mainly Constipation 19.8% 18.4% NS
Mainly Diarrhea 20.1% 19.5% NS
Depression (BSI) 5.0 (4.4) 3.5 (4.8) p < .001
Anxiety (BSI) 4.5 (5.0) 2.9 (3.7) p < .001
Somatization (BSI) 4.6 (4.4) 3.5 (3.8) p < .001
Quality of Life (IBSQoL) 75.1 (20.6) 81.0 (18.6) p < .001
Pharmacy Costs $1084 (1588) $1049 (1793) NS
Lower GI costs $628 (1142) $454 (522) NS
Total health expenditures $6059 (6628) $6111 (8771) NS
Non-prescription costs $325 (369) $192 (215) p < .001
Satisfaction with physician care at index visit (0–100) 65.9 (27.1) 68.3 (25.5) NS
Satisfactory relief of bowel Sx at follow up (% responding yes) 59.5% 63.9% p < .01
Somewhat to remarkable change in bowel symptoms 53.7% 53.7% NSPage 5 of 7
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root/tea, massage therapy and yoga. The use of herbal
therapies is similar to that in the US population [1] and
the choice of ginger, the most popular herb, is explained
by its widely suggested use for digestive problems. Several
small clinical trials have supported the use of ginger as an
antiemetic [20], and evidence is building for its anti-
inflammatory properties [21]. The most frequently used
alternative care (ginger, massage therapy and yoga) have
rarely been investigated for FBDs. Hypnosis, acupuncture
and peppermint oil have shown considerable benefit in a
few randomized controlled trials for IBS [22,23] but are
used by relatively few patients.
In the current study we defined CAM as therapies not part
of conventional medicine. We chose not to include other
therapies, such as fiber and probiotics, that other authors
have described as CAM [8,10,24]. This decision was based
on a determination that both probiotics and fiber are
increasingly recommended for FBDs (both are available
over the counter in the United States), and as such are
more likely to be considered part of conventional medi-
cine, rather than CAM [25,26].
The effect of CAM on conventional care
The data suggest that using CAM does not decrease a
patient's willingness to use conventional medical care.
Cost of conventional care was not different between CAM
and non-CAM users, CAM use was not associated with dis-
satisfaction with physician care at the index visit, or with
perceived effectiveness of prescription medications and
satisfactory relief at 6-month follow-up. However, CAM
users did report more gastrointestinal symptoms at fol-
low-up. While this association is causally ambiguous, the
fact that CAM users had greater symptoms severity and
greater quality of life impairment 6 months earlier sug-
gests that CAM use is driven by disease severity rather than
dissatisfaction with care. From the current data set we do
not know why CAM use was not associated with dissatis-
faction with conventional medicine. Follow-up studies
are needed to study this relationship in depth.
Physicians should ask whether their patients are using
CAM for at least two reasons: (1) prescribed drugs may
interact with CAM or non-prescription drugs in ways that
affect the safety and efficacy of the prescribed medica-
tions, and (2) physicians may wish to recommend empir-
ically supported CAM therapies to their patients who are
not using them. Koretz and Rotblatt advise in a recent
review that "Gastroenterologists should become familiar
with these techniques; it is likely their patients already are
[27]." Referrals to CAM providers were infrequent in the
current study, and confidence among patients in these
treatments was low. However, physician recommenda-
tion to see a CAM provider was followed by most patients
in our study, indicating a willingness of patients to con-
sider CAM as a treatment alternative for their symptoms.
Differences between CAM and non-CAM users
CAM use was associated with age, gender, education level,
IBS severity, less satisfactory relief of symptoms, abdomi-
nal distention, psychological distress, and non prescrip-
tion drug costs. Of these, only gender, college education
and anxiety remained significant in a multivariate analy-
sis. The association with psychological distress indicates a
possible role for poor coping with symptoms in seeking
alternative care. This finding is in contrast with the obser-
vations of Koloski and colleagues [7] who found that
seeking care from an alternative health care provider was
not related to psychological morbidity. The current study
has focused on the use of a wide range of CAM -including
self prescribed remedies- not only self-referral to a CAM
provider which may explain the different findings.
Limitations of the study
This study was limited by recruiting among HMO patients
in an urbanized area in Western US. The findings may
therefore have limited generalizability to uninsured
patients, Medicare patients, or patients in non-urban
areas. However, the demographics of the HMO member-
ship are largely similar to that of the Unites States. In addi-
tion, any survey has the potential weakness of self-
selection bias by people with certain characteristics. As we
have no data on non-responders we cannot exclude self-
selection bias. However, our response rate was well within
the acceptable limits for medical research (59%), and
CAM use was not the sole or main focus of the study and
thus it is unlikely that patients self-selected on this crite-
rion.
Secondly, patients did not specify if they used the CAM
therapies for their bowel problems, to treat other symp-
toms, or simply to increase quality of life. The associations
between CAM use and bowel disorders are therefore ten-
tative. Additional limitations are the dependence on self-
report for CAM and non-prescription cost data, and the
categorical nature and ceiling limitation of its reporting.
As a consequence, real CAM costs may be higher than
reported in this study.
Conclusion
In conclusion, CAM use is common in patients with FBD,
but does not appear to be driven by perceived ineffective-
ness of conventional medicine. Not all patients may be
able to afford CAM due to its out-of-pocket costs. By mov-
ing CAM therapies with proven effectiveness into regular
care, and providing insurance reimbursement for them,
CAM can become more widely available. For this to occur
we need to fill current knowledge gaps about treatment
effectiveness (such as in herbal therapies) and make treat-Page 6 of 7
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therapy and psychotherapy, more readily accessible.
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